Free Trial

Innospec Inc. (NASDAQ:IOSP) Receives Consensus Recommendation of "Hold" from Analysts

Innospec logo with Basic Materials background

Key Points

  • Innospec Inc. has received a consensus recommendation of "Hold" from three analysts, with ratings varying from sell to strong buy.
  • Following recent earnings, the company reported a 1.1% increase in revenue year-over-year, with earnings per share of $1.26, surpassing the estimates of $1.17.
  • Approximately 96.64% of Innospec's stock is held by institutional investors, indicating strong institutional confidence in the company.
  • MarketBeat previews top five stocks to own in November.

Innospec Inc. (NASDAQ:IOSP - Get Free Report) has earned an average recommendation of "Hold" from the three ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and one has issued a strong buy rating on the company.

A number of analysts have issued reports on the company. Zacks Research raised Innospec from a "strong sell" rating to a "hold" rating in a research note on Monday. Wall Street Zen downgraded Innospec from a "buy" rating to a "hold" rating in a research report on Saturday, September 20th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Innospec in a research report on Saturday, September 27th.

Read Our Latest Research Report on IOSP

Innospec Stock Performance

Shares of IOSP stock opened at $78.10 on Wednesday. Innospec has a fifty-two week low of $74.10 and a fifty-two week high of $128.35. The firm has a market capitalization of $1.94 billion, a P/E ratio of 100.13 and a beta of 1.04. The stock's fifty day moving average is $82.07 and its two-hundred day moving average is $85.75.

Innospec (NASDAQ:IOSP - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty chemicals company reported $1.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.17 by $0.09. Innospec had a return on equity of 10.89% and a net margin of 1.08%.The business had revenue of $439.70 million during the quarter, compared to the consensus estimate of $440.70 million. During the same period last year, the company earned $1.39 EPS. The company's revenue for the quarter was up 1.1% on a year-over-year basis. On average, equities analysts forecast that Innospec will post 6.18 earnings per share for the current year.

Institutional Trading of Innospec

Hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. increased its position in shares of Innospec by 2.4% during the 1st quarter. Principal Financial Group Inc. now owns 132,493 shares of the specialty chemicals company's stock worth $12,554,000 after purchasing an additional 3,045 shares during the last quarter. Rhumbline Advisers increased its position in shares of Innospec by 9.3% during the 1st quarter. Rhumbline Advisers now owns 77,760 shares of the specialty chemicals company's stock worth $7,368,000 after purchasing an additional 6,602 shares during the last quarter. American Century Companies Inc. increased its position in shares of Innospec by 27.7% during the 1st quarter. American Century Companies Inc. now owns 47,545 shares of the specialty chemicals company's stock worth $4,505,000 after purchasing an additional 10,309 shares during the last quarter. Voya Investment Management LLC increased its position in shares of Innospec by 63.2% during the 1st quarter. Voya Investment Management LLC now owns 327,289 shares of the specialty chemicals company's stock worth $31,011,000 after purchasing an additional 126,750 shares during the last quarter. Finally, Intech Investment Management LLC grew its position in Innospec by 30.7% in the 1st quarter. Intech Investment Management LLC now owns 22,023 shares of the specialty chemicals company's stock valued at $2,087,000 after acquiring an additional 5,178 shares in the last quarter. 96.64% of the stock is owned by institutional investors and hedge funds.

About Innospec

(Get Free Report)

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Innospec Right Now?

Before you consider Innospec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innospec wasn't on the list.

While Innospec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.